- Home
- EIC vs YMAB Comparison
EIC vs YMAB Comparison
Compare EIC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- YMAB
- Stock Information
- Founded
- EIC N/A
- YMAB 2015
- Country
- EIC United States
- YMAB United States
- Employees
- EIC N/A
- YMAB N/A
- Industry
- EIC Finance/Investors Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- YMAB Health Care
- Exchange
- EIC Nasdaq
- YMAB Nasdaq
- Market Cap
- EIC 355.7M
- YMAB 218.4M
- IPO Year
- EIC 2019
- YMAB 2018
- Fundamental
- Price
- EIC $14.36
- YMAB $4.04
- Analyst Decision
- EIC Strong Buy
- YMAB Buy
- Analyst Count
- EIC 1
- YMAB 11
- Target Price
- EIC $17.50
- YMAB $18.73
- AVG Volume (30 Days)
- EIC 186.3K
- YMAB 204.4K
- Earning Date
- EIC 05-20-2025
- YMAB 05-13-2025
- Dividend Yield
- EIC 16.67%
- YMAB N/A
- EPS Growth
- EIC N/A
- YMAB N/A
- EPS
- EIC 1.97
- YMAB N/A
- Revenue
- EIC $46,223,036.00
- YMAB $87,685,000.00
- Revenue This Year
- EIC $39.61
- YMAB N/A
- Revenue Next Year
- EIC $27.28
- YMAB $18.83
- P/E Ratio
- EIC $7.33
- YMAB N/A
- Revenue Growth
- EIC 72.79
- YMAB 3.38
- 52 Week Low
- EIC $12.73
- YMAB $3.84
- 52 Week High
- EIC $16.71
- YMAB $17.47
- Technical
- Relative Strength Index (RSI)
- EIC 50.89
- YMAB 42.87
- Support Level
- EIC $13.82
- YMAB $4.02
- Resistance Level
- EIC $14.67
- YMAB $4.60
- Average True Range (ATR)
- EIC 0.22
- YMAB 0.32
- MACD
- EIC 0.11
- YMAB -0.01
- Stochastic Oscillator
- EIC 72.07
- YMAB 23.93
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.